Technical Data
C9097-29A
Cytokeratin 20 (FITC)
Description:
Represents an excellent marker for certain types of carcinomas such as adenocarcinomas of the colon, transitional cell carcinomas of the bladder and Merkel cell tumors of the skin. Very sensitive detection of intestestinal and gastric foveolar epithelium, urothelial umbrella cells, Merkel cells of epidermis as well as tumors originating therefrom (e.g. primary and metastatic colorectal carcinoma). Adenocarcinomas of breast, lung, endometrium and ovary (non-mucinous) as well as neuroendocrine tumors of the lung are essentially negative.

Applications:
Suitable for use in Flow Cytometry, Immunocytochemistry and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry (Frozen, Paraffin): 1:10-1:20 in PBS, pH 7.4. Incubate for 1 hour at RT or overnight at 2-8C. Microwave treatment required for paraffin sections.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG15F216Affinity Purified
SizeStorageShippingSourceHost
250ul-20CBlue IceHumanMouse
Concentration:
~0.2mg/ml
Immunogen:
Electrophoretically purified Cytokeratin (CK) 20 from human intestinal mucosa.
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4. Labeled with fluorescein isothiocyanate (FITC).
Specificity:
Recognizes human Cytokeratin 20, Mr 46kD. Reactivities on Cultured Cell Lines: HT-29, LoVo, DLD-1, SW 1116, CaCo-2, RT-4. Species Crossreactivity: porcine and rat. Does not recognize mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Moll, R., et al., Am. J. Path. 140: 427-447 (1992). 2. Moll, R., et al., J. Cell. Biol. 111: 567-580 (1990). 3. Moll, I. & Moll, R., Arch. Dermatol. Res. 283: 300-309 (1991). 4. Moll, R., et al., Differentiation 53: 75-93 (1993). 5. Mbus, V.J., et al., Br. J. Cancer 69: 422-428 (1994). 6. Demirkesen, C., et al., J. Cutan. Pathol. 22: 518-535 (1995). 7. Zhang, C. & Oakley, B., Differentiation 61: 121-127 (1996). 8. Harnden, P., et al., British Journal of Cancer 78: 870-875 (1996).